The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The c ‐ erbB ‐ 2 proto‐oncogene in human pancreatic cancer
Abstract
The c ‐ erbB ‐ 2 oncogene encodes a 190 kD transmembrane growth factor receptor which is closely related to the EGF receptor and has been found to be amplified and overexpressed in a number of human adenocarcinomas, particularly of the breast. We have analysed, by immunocytochemistry using the 21N antibody, expression of c ‐ erbB ‐ 2 in a retrospective series of pancreatic adenocarcinoma, chronic pancreatitis, and examples of histologically normal pancreas. In three cases (21 per cent) of chronic pancreatitis, there were focal areas of cytoplasmic immunoreactivity in regenerating epithelium. In 15 cases (17 per cent) of pancreatic adenocarcinoma, cytoplasmic immunoreactivity was seen, while in two cases (2 per cent) strong membrane staining of tumour cells was seen which could be blocked by peptide controls. c ‐ erbB ‐ 2 immunoreactivity was also demonstrated using a second antibody, 20N, which recognizes another peptide sequence of the c ‐ erbB ‐ 2 protein. There was no relationship between immunoreactivity and histological subtype or grade, but there was absolute concordance between staining in primary and metastatic deposits. Since the rat homologue ( neu ) of the c ‐ erbB ‐ 2 oncogene may be activated by a specific point mutation in its transmembrane region, we have analysed 23 cases from this series for mutations by polymerase chain reaction amplification and sequence‐specific oligonucleotide hybridization. We were unable to identify activity mutations in this series. These data suggest that there is abnormal expression of c ‐ erbB ‐ 2 oncogene in nearly 20 per cent of cases although mutational activation of this gene is not seen in human pancreatic adenocarcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Cited by
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Friess, H., Yamanaka, Y., Büchler, M., Ebert, M., Beger, H. G., Gold, L. I., & Korc, M. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)91084-u · Cited by 522
Immunohistochemistry as an Important Tool in Biomarkers Detection and Clinical Practice
De Matos, L. L., Trufelli, D. C., De Matos, M. G. L., & Da Silva Pinhal, M. A. (2010) · Biomarker Insights · doi:10.4137/bmi.s2185 · Cited by 437
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer
Barton, C., Staddon, S., Hughes, C., Hall, P., O'Sullivan, C., Klöppel, G., Theis, B., Russell, R., Neoptolemos, J., & Williamson, R. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.467 · Cited by 376
Self-citationGenetic progression in the pancreatic ducts
Hruban, R. H., Wilentz, R. E., & Kern, S. E. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65054-7 · Cited by 373
Metadata
- Authors
- Hall, P. A., Hughes, C. M., Staddon, S. L., Richman, P. I., Gullick, W. J., & Lemoine, N. R.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 1990-07
- Volume
- 161
- Issue
- 3
- Pages
- 195-200
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2041254255
- Cited by
- 171
- References
- 1
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The c ‐ erbB ‐ 2 proto‐oncogene in human pancreatic cancer. https://app.cochat.ai/papers/10.1002/path.1711610305
- The paper
- Hall, P. A., Hughes, C. M., Staddon, S. L., Richman, P. I., Gullick, W. J., & Lemoine, N. R. (1990). The c ‐ erbB ‐ 2 proto‐oncogene in human pancreatic cancer. The Journal of Pathology. https://doi.org/10.1002/path.1711610305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.